Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today the enrollment of the first patient in a Phase ...
After dying and coming back to life, Sammy Berko, 17, was diagnosed with a rare genetic heart condition, catecholaminergic polymorphic ventricular tachycardia (CPVT) Wendy Grossman Kantor is an ...
CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and ...
- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
A Newport News family said they are battling a rare heart disease, known as catecholaminergic polymorphic ventricular tachycardia, also known as CPVT, which has severely ...
CRESTON, Iowa -- Five months after collapsing at a spring track meet, 15-year-old Nate Bentley is back under the Friday night lights - this time with a personalized plan and a heart monitor helping ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results